MXPA05005314A - Compuestos de lapacona novedosos y metodos de uso de los mismos. - Google Patents

Compuestos de lapacona novedosos y metodos de uso de los mismos.

Info

Publication number
MXPA05005314A
MXPA05005314A MXPA05005314A MXPA05005314A MXPA05005314A MX PA05005314 A MXPA05005314 A MX PA05005314A MX PA05005314 A MXPA05005314 A MX PA05005314A MX PA05005314 A MXPA05005314 A MX PA05005314A MX PA05005314 A MXPA05005314 A MX PA05005314A
Authority
MX
Mexico
Prior art keywords
methods
compounds
lapachone compounds
novel
prevention
Prior art date
Application number
MXPA05005314A
Other languages
English (en)
Inventor
Zhiwei Jiang
Original Assignee
Arqule Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arqule Inc filed Critical Arqule Inc
Publication of MXPA05005314A publication Critical patent/MXPA05005314A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D335/08—Naphthothiopyrans; Hydrogenated naphthothiopyrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/92—Naphthofurans; Hydrogenated naphthofurans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/92—Naphthopyrans; Hydrogenated naphthopyrans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D327/00—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D327/02—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom
    • C07D327/06—Six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/74—Naphthothiophenes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invencion proporciona analogos y derivados de lapacona, asi como metodos de uso de los mismos. Estos compuestos pueden utilizarse en composiciones farmaceuticas para el tratamiento o prevencion de trastornos de la proliferacion celular. Estos compuestos tambien pueden utilizarse en el tratamiento o prevencion de la soriasis o el cancer o condiciones precancerosas.
MXPA05005314A 2002-11-18 2003-11-18 Compuestos de lapacona novedosos y metodos de uso de los mismos. MXPA05005314A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42728302P 2002-11-18 2002-11-18
PCT/US2003/037219 WO2004045557A2 (en) 2002-11-18 2003-11-18 Novel lapachone compounds and methods of use thereof

Publications (1)

Publication Number Publication Date
MXPA05005314A true MXPA05005314A (es) 2005-10-19

Family

ID=34375156

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05005314A MXPA05005314A (es) 2002-11-18 2003-11-18 Compuestos de lapacona novedosos y metodos de uso de los mismos.

Country Status (12)

Country Link
US (1) US20040266857A1 (es)
EP (1) EP1567515A4 (es)
JP (1) JP2006508147A (es)
CN (1) CN1729183A (es)
AR (1) AR056613A1 (es)
AU (1) AU2003295738A1 (es)
BR (1) BR0316296A (es)
CA (1) CA2506340A1 (es)
EA (1) EA200500849A1 (es)
MX (1) MXPA05005314A (es)
TW (1) TW200510367A (es)
WO (1) WO2004045557A2 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004050033A2 (en) 2002-12-02 2004-06-17 Arqule, Inc. Method of treating cancers
EP1694322A2 (en) 2003-11-26 2006-08-30 Arqule, Inc. Use of beta-lapachone for protecting against radiation injury
WO2005082353A2 (en) * 2004-02-20 2005-09-09 Arqule, Inc. Use of beta-lapachone for treating or preventing cancer
JP2007523191A (ja) * 2004-02-20 2007-08-16 アークル・インコーポレーテツド 血液腫瘍の治療のためのβ−ラパコンの使用
US20050187288A1 (en) * 2004-02-20 2005-08-25 Chiang Li Beta-lapachone and methods of treating cancer
CA2556823A1 (en) * 2004-02-20 2005-09-09 Arqule, Inc. Use of beta-lapachone for the treatment of lung cancer
WO2005082359A2 (en) * 2004-02-20 2005-09-09 Arqule, Inc. Use of beta-lapachone for the treatment of pancreatic cancer
CA2555941A1 (en) 2004-02-20 2005-09-09 Arqule, Inc. Use of beta-lapachone for treatment of colon cancer
WO2005082358A2 (en) * 2004-02-20 2005-09-09 Arqule, Inc. Use of beta-lapachone as a broad spectrum anti-cancer agent
US8614228B2 (en) 2004-08-11 2013-12-24 Arqule, Inc. Quinone prodrug compositions and methods of use
US7812051B2 (en) 2004-08-11 2010-10-12 Arqule, Inc. Pharmaceutical compositions of β-lapachone and β-lapachone analogs with improved tumor targeting potential
CA2594234A1 (en) 2005-01-07 2006-07-27 Arqule, Inc. Compositions for modulation of parp and methods for screening for same
WO2006128120A2 (en) * 2005-05-26 2006-11-30 Arqule, Inc. Novel lapachone compounds and methods of use thereof
WO2007139569A1 (en) * 2006-05-26 2007-12-06 Arqule, Inc. Novel lapachone compounds and methods of use thereof
TW200824692A (en) 2006-08-21 2008-06-16 Arqule Inc Novel lapachone compounds and methods of use thereof
EP2137168B1 (en) * 2007-03-16 2016-09-14 Lankenau Institute for Medical Research Novel ido inhibitors and methods of use thereof
WO2008134088A1 (en) 2007-04-30 2008-11-06 Arqule, Inc. Hydroxy sulfonate of quinone compounds and their uses
WO2009051752A1 (en) * 2007-10-16 2009-04-23 Arqule, Inc. Novel lapachone compounds and methods of use thereof
KR101405823B1 (ko) * 2007-12-24 2014-06-12 주식회사 케이티앤지생명과학 녹내장의 치료 및 예방을 위한 약제 조성물
KR20090071829A (ko) * 2007-12-28 2009-07-02 주식회사 머젠스 신장질환의 치료 및 예방을 위한 약제 조성물
KR20090073381A (ko) * 2007-12-31 2009-07-03 주식회사 머젠스 심장질환의 치료 및 예방을 위한 약제 조성물
RU2012156842A (ru) * 2010-06-01 2014-07-20 Белле-Эйр Фрейгренсиз, Инк. Способ и продукт для борьбы с запахом изо рта
US10829427B2 (en) 2015-12-18 2020-11-10 The Board Of Regents Of The University Of Texas System Naphthoquinones, pro-drugs, and methods of use thereof
KR101735275B1 (ko) 2016-12-20 2017-05-16 아주대학교산학협력단 베타-라파촌을 포함하는 수면 장애 예방 또는 치료용 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2011455B (en) * 1977-12-21 1982-03-03 Ici Ltd Chemical process
US5346917A (en) * 1991-06-10 1994-09-13 Sterling Winthrop Inc. Thioxanthenone antitumor agents
US5763625A (en) * 1995-04-25 1998-06-09 Wisconsin Alumni Research Foundation Synthesis and use of β-lapachone analogs
US6245807B1 (en) * 1995-08-24 2001-06-12 Dana-Farber Cancer Institute Treatment of human prostate disease
US5824700A (en) * 1996-02-20 1998-10-20 Wisconsin Alumni Research Foundation Ortho-quinone derivatives novel synthesis therefor and their use in the inhibition of neoplastic cell growth
US5883270A (en) * 1996-02-20 1999-03-16 Wisconsin Alumni Research Foundation 4-substituted-1, 2-naphthoquinones and their use in the inhibition of neoplastic cell growth
WO2000061142A1 (en) * 1999-04-14 2000-10-19 Dana-Farber Cancer Institute, Inc. Method and composition for the treatment of cancer
WO2004007531A2 (en) * 2002-07-17 2004-01-22 Arqule, Inc. Activated checkpoint therapy and methods of use thereof

Also Published As

Publication number Publication date
JP2006508147A (ja) 2006-03-09
US20040266857A1 (en) 2004-12-30
CA2506340A1 (en) 2004-06-03
BR0316296A (pt) 2005-12-13
EP1567515A2 (en) 2005-08-31
EP1567515A4 (en) 2008-04-23
WO2004045557A2 (en) 2004-06-03
AR056613A1 (es) 2007-10-17
AU2003295738A1 (en) 2004-06-15
TW200510367A (en) 2005-03-16
CN1729183A (zh) 2006-02-01
EA200500849A1 (ru) 2006-02-24
WO2004045557A3 (en) 2004-08-12

Similar Documents

Publication Publication Date Title
MXPA05005314A (es) Compuestos de lapacona novedosos y metodos de uso de los mismos.
IL251185A0 (en) mek inhibitors and methods of using them
MXPA05005223A (es) Diaminotriazoles utiles como inhibidores de proteinas cinasas.
IL181700A0 (en) Quinazoline derivatives and pharmaceutical compositions containing the same
GEP20094845B (en) Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
AU2004263179A8 (en) Heteroarylaminosulfonylphenyl derivatives for use as sodium or calcium channel blockers in the treatment of pain
TW200510416A (en) P38 inhibitors and methods of use thereof
EP1485381B8 (en) Azolylaminoazine as inhibitors of protein kinases
WO2006107451A3 (en) Honokiol derivatives for the treatment of proliferative disorders
IL217623A (en) Amino-carbonyl-boron compound is converted
AU2003220300A1 (en) Compositions useful as inhibitors of protein kinases
TW200608979A (en) Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
IL171974A0 (en) Tetrahydrocarbazole derivatives and their pharmaceutical use
PL1654253T3 (pl) Podstawione pochodne 3-pirolidynoindolu
TW200716091A (en) New therapeutic combinations for the treatment or prevention of psychotic disorders
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
IL179206A0 (en) Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same
UA89201C2 (ru) Энантиомеры выбранных конденсированных пиримидонов и их применение для лечения и профилактики злокачественного новообразования
WO2004026253A3 (en) Novel lapacho compounds and methods of use thereof
BRPI0411864A (pt) combinação de inibidores de src quinase e agentes quimioterápicos para o tratamento de doenças proliferativas
MY162518A (en) Proteasome inhibitors and methods of using the same
WO2006128120A3 (en) Novel lapachone compounds and methods of use thereof
GB0407025D0 (en) Novel compounds
HK1088214A1 (en) Pmcol for the treatment of prostate cancer
HK1082727A1 (en) 2" oxo-voruscharin and derivatives thereof

Legal Events

Date Code Title Description
FA Abandonment or withdrawal